Sumitomo Pharma Co., Ltd.(4506) News

Submission of the Application of Manufacturing and Marketing Authorization for iPS Cell-Derived dopaminergic neural progenitor cells in Japan

Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2026

Presentation Material (Conference on Q1 FY2025 Financial Results)

Notice Concerning Finance Costs

(Progress of Disclosure Matters) Completion of Procedures for Company Split of Asian Business and Share Transfer to Marubeni Global Pharma

Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS]

Sumitomo Pharma, Returning to Profitability This Year

Corporate Governance Report

Matters Concerning Controlling Shareholders, Etc.

Notice of Assignment of Assets for Key Products in the U.S. within Sumitomo Pharma Group

(Progress of disclosure matters) Notice Regarding a Company Split of the Asian Business and Share Transfer with Marubeni Global Pharma Corporation

Supplementary Financial Data (IFRS) for the Year Ended March 31, 2025

Summary of Consolidated Financial Results for the Year Ended March 31, 2025 [IFRS]

Presentation Material Conference on FY2024 Financial Results and Reboot 2027 Reboot for a Strong Sumitomo Pharma

Sumitomo Pharma Announces Reboot 2027 - Reboot for a Strong Sumitomo Pharma -

Notice Regarding the Estimated Recording of Gain on Transfer of Shares in Affiliated Companies

Notice of Partial Amendment to the Articles of Incorporation

Notice Regarding Appointment of Executive and Other Key Personnel

Sumitomo Pharma, 69% Increase in Net Income for The Current Fiscal Year

Notice Concerning Reversal of Allowance for Doubtful Accounts of Subsidiaries and Affiliates in Company’s Non-consolidated Financial Statements